Fas/FasL and Apoptosis/Non-apoptosis
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i3.2765
Abstract
The interaction of Fas and Fas ligand (FasL) is an important player in regulating apoptosis while Fas/FasL is also found to be involved into non-apoptosis regulation, which made it more attractive. To understand Fas/Fas ligand (FasL) and its function in the apoptosis and non-apoptosis regulation, a wide search was done by using internationally well-known databases and relevant papers were selected. Evidences supported that Fas/FasL signaling apoptotic pathway played a crucial role in the regulation of cell death and proliferation in various cell types. Numerous molecules were involved in the precise regulation of Fas/FasL mediated apoptosis through complicated signalling cascades. Nevertheless, the traditional apoptotic pathway, Fas/FasL signaling pathway, was also disclosed to function in non-apoptotic regulation in T cells via the interaction between T cell receptor and Fas/FasL and therefore Fas/FasL could be pivotal in maintaining the homeostasis of peripheral T cells and immune system.
Keywords
Fas/CD95, Fas ligand/CD95L/CD178, apoptosis, non-apoptosis
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
Yonehara S, Ishii A, Yonehara M , et al. A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J ExpMed. 1989;169:1747-56.
Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. J Science. 1989;245:301-5.
Papoff G, Cascino I, Eramo A, et al. An N-terminal domain shared by Fas/Apo-1(CD95) soluble variants prevents cell death in vitro. J Immunol. 1996;156:4623-630.
Cheng JH, Zhou T, Liu CD, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759-62.
Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med. 2000; 191:1209-20.
Calmon-Hamaty F, Audo R, Combe B, et al. Targeting the Fas/FasL system in rheumatoid arthritis therapy: promising or risky? Cytokine. 2015;75:228-33.
Krammer PH, Daniel J, Walaczak H, et al. The role of APO-1-mediated apoptosis in immune system. Immunol Rew.1994;142:175-91.
Orlinick JR, Elkon KB, Chao MV. Separate domains of the human fas ligand dictate self-association and receptor binding. J Biol Chem. 1997;272:32221-9.
Zhu Y, Swanson BJ, Wang M, et al. Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc Natl Acad Sci U S A. 2004;101:7681-6.
Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002; 3:221-7.
Green DR. Ware CF. Fas-ligand: previlege and peril. Proc Natl Acad Sci USA. 1997;94:5986-90.
Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol. 2009;10:348-55.
Yamada A, Arakaki R, Saito M, et al. Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Front Immunol. 2017;8:403.
Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007;13:1070-7.
Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol. 2010;11:21-7.
Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181:71-7.
Singer GG, Carrera AC, Marshak-Rothstein A, et al. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol. 1994;6:913-20.
Roberts AI, Devadas S, Zhang X, et al. The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol Res. 2003;28:285-93.
Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10:124-33.
Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ. 2012;19:36-41.
Golks A, Brenner D, Krammer PH, Lavrik IN. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J Exp Med. 2006;203:1295-305.
Jaleco S, Swainson L, Dardalhon V, et al. Homeostasis of naive and memory CD4+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J Immunol. 2003;171:61-8.
Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. J Science. 1989;245:301-5.
Papoff G, Cascino I, Eramo A, et al. An N-terminal domain shared by Fas/Apo-1(CD95) soluble variants prevents cell death in vitro. J Immunol. 1996;156:4623-630.
Cheng JH, Zhou T, Liu CD, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759-62.
Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med. 2000; 191:1209-20.
Calmon-Hamaty F, Audo R, Combe B, et al. Targeting the Fas/FasL system in rheumatoid arthritis therapy: promising or risky? Cytokine. 2015;75:228-33.
Krammer PH, Daniel J, Walaczak H, et al. The role of APO-1-mediated apoptosis in immune system. Immunol Rew.1994;142:175-91.
Orlinick JR, Elkon KB, Chao MV. Separate domains of the human fas ligand dictate self-association and receptor binding. J Biol Chem. 1997;272:32221-9.
Zhu Y, Swanson BJ, Wang M, et al. Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc Natl Acad Sci U S A. 2004;101:7681-6.
Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002; 3:221-7.
Green DR. Ware CF. Fas-ligand: previlege and peril. Proc Natl Acad Sci USA. 1997;94:5986-90.
Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol. 2009;10:348-55.
Yamada A, Arakaki R, Saito M, et al. Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Front Immunol. 2017;8:403.
Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007;13:1070-7.
Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol. 2010;11:21-7.
Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181:71-7.
Singer GG, Carrera AC, Marshak-Rothstein A, et al. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol. 1994;6:913-20.
Roberts AI, Devadas S, Zhang X, et al. The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol Res. 2003;28:285-93.
Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10:124-33.
Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ. 2012;19:36-41.
Golks A, Brenner D, Krammer PH, Lavrik IN. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J Exp Med. 2006;203:1295-305.
Jaleco S, Swainson L, Dardalhon V, et al. Homeostasis of naive and memory CD4+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J Immunol. 2003;171:61-8.
Copyright © 2024 Yifei Yu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License